Norditropin Growth Hormone Injection Approved for Marketing in China

On December 25th, according to Novo Nordisk, the National Medical Products Administration officially approved the listing application of Norditropin, a long-acting growth hormone injection developed and produced by Novo Nordisk, for the treatment of growth retardation caused by insufficient secretion of endogenous growth hormone in children aged 2.5 years and older.